News
Scientists find red blood cell-like structures in a dinosaur fossil, shedding light on cancer’s ancient origins.
Imagine cells navigating through a complex maze, guided by chemical signals and the physical landscape of their environment.
New techniques used to analyze soft tissue in dinosaur fossils may hold the key to new cancer discoveries, according to a ...
Nearly half of sequencing data labeled as endometriosis lacks true disease representation, highlighting the urgent need for more diverse and accurate tissue sampling to advance research in this ...
To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...
kDepartment of Gynecology and Obstetrics, Hospital Anregiomed Ansbach, Ansbach, Germany lDepartment of Obstetrics and Gynecology, University Hospital Aachen, Aachen, Germany mViDia Christliche ...
New research led by Irish scientists has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body's immune response in advanced ovarian cancer.
"This work adds a critical piece to the puzzle of why ovarian cancer is so aggressive and has such poor outcomes. While the immune system is naturally equipped to detect and destroy cancer cells ...
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line treatment for adult patients with KRAS-mutat ...
A woman's chances of surviving ovarian cancer at least five years after diagnosis come down to the toss of a coin: just 49% will reach that milestone, making it one of the most lethal reproductive ...
The FDA approved Avmapki Fakzynja Co-pack for KRAS-mutated, recurrent, low-grade serous ovarian cancer after prior systemic therapy. The RAMP-201 trial showed a 44% response rate, with response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results